Hepatitis is the inflammation of the liver. The condition can be limited to self or can advance to scarring, cirrhosis or liver cancer. Hepatitis viruses are the most common origin of Hepatitis in all over the world. Sometimes, other infections, toxic substances (e.g. alcohol, certain drugs), and autoimmune diseases can also cause Hepatitis.

1. Focus keyword- Hepatitis market
Hepatitis market Overview
Hepatitis is the inflammation of the liver. The condition can be limited to self or can advance to scarring,
cirrhosis or liver cancer. Hepatitis viruses are the most common origin of Hepatitis in all over the world.
Sometimes, other infections, toxic substances (e.g. alcohol, certain drugs), and autoimmune diseases can
also cause Hepatitis.
“Nearly 1 million people die every year worldwide due to Hepatitis”
Hepatitis types
Hepatitis classification is based on the two types. One is acute if the condition lasts for less than six months
and chronic when the condition persists for more than six months. Based on disease type, the hepatitis
therapeutics market is segmented into A, B, C, and others. The other segment covers the hepatitis market
that estimates for hepatitis D and E, which occur rarely compared to the other three conditions.
The access to hepatitis treatments of this disease has been limited to people who have a high-income
level owing to high drug price, which might act as a restraining factor for the hepatitis market. The
hepatitis market dynamics will change globally because of the introduction of generic versions of drugs.
Hepatitis market
The global therapeutics hepatitis market size was estimated at USD 19 billion in 2016 and is pegged at a
CAGR of 3% during the forecast period for hepatitis market size forecast. There are a few prominent
factors that are expected to boost the hepatitis market; they are growing viral Hepatitis prevalence, rise
in the number of autoimmune diseases, and the surge in healthcare expenditures across the globe.
The therapeutics hepatitis market share analysis is mainly dominated by North America, followed by
Europe and the Asia Pacific. In 2016, the North America hepatitis market forecast accounted for 43 % of
revenue mainly due to the high demand in the U.S., relatively higher affordability of patient population,
and awareness about advance therapeutics in the region.
Hepatitis B Virus Overview
One of the viruses is the Hepatitis B Virus (HBV) that causes Hepatitis B, which is a life-threatening liver
infection. It is a significant concern and a significant global health problem. It can be an acute infection or
a chronic infection. Chronic Hepatitis B Virus infection is the leading cause of chronic Hepatitis and
advanced-stage liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). Hepatitis B virus is
a blood-borne and sexually-transmitted virus, which is acquired by percutaneous and mucosal exposure
to blood or/ and body fluids of an infected person. The clinical manifestations of Hepatitis from different
origins may be quite similar.
Hepatitis B Virus Infection is estimated to have 786,000 deaths and the vast majority being attributable
to liver cancer (341,000 deaths) and cirrhosis (312,000 deaths). Hepatitis B Virus infection ranks 15th
among all causes of human mortality. Around two billion people globally have been infected with the
Hepatitis B Virus infection and about 360 million live with chronic Hepatitis B infection. The Hepatitis B

2. Virus prevalence in the general population is heterogeneous in Europe, ranging 0.1-7 % depending on the
country. The Hepatitis B Virus global prevalence varies widely. It ranges from 0.5 % in areas of low
endemicity (e.g., North America and some Western European countries) to rates above 8% in the highly
endemic countries of Sub- Saharan Africa and East Asia.
Hepatitis B virus market
Now taking into consideration of Hepatitis B virus market, it is dominated by chronic Hepatitis B
medication, which focuses on viral suppression and includes two therapy classes, oral nucleoside
analogues (NUC) – Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) and pegylated
interferon (PEG-IFN). For acute hepatitis B infection, no specific treatment is available; only care is focused
on maintaining comfort and required nutritional balance, including replacement of fluids (lost due to
vomiting), etc.
Many companies are developing drugs for Hepatitis B Virus market treatment. DelveInsight is one such
company that prepares market reports, pipeline reports, and epidemiology reports. It proffers a detailed
overview of the Hepatitis B Virus market and an in-depth comprehension of the historical and forecasted
Hepatitis B Virus market epidemiology. It shows Hepatitis B Virus market treatment patterns, potential
upcoming drugs and also recognises the best of the Hepatitis B Virus market opportunities by showing the
current and forecasted Hepatitis B Virus market revenue, trends of sales, and uptake of drugs during the
study period from 2017-2028. The Hepatitis B Virus market report also proffers in-depth analysis of the
disease overview by including details like disease definition, classification, symptoms, aetiology,
pathophysiology and diagnostic trends. The exhaustive details about Hepatitis B Virus market treatment
algorithms and treatment guidelines in the United States, Europe, and Japan are also provided in the
report.